| Reporting Period | Filing Date | Average Time to Pay (days) | Paid within 30 days | Paid 31-60 days | Paid after 60 days | Not Paid within Terms |
|---|---|---|---|---|---|---|
| 01 Jul 2025 - 31 Dec 2025 | 27 Jan 2026 | 19 | 82% | 8% | 10% | 49% |
| 01 Jan 2025 - 30 Jun 2025 | 11 Jul 2025 | 25 | 77% | 9% | 14% | 63% |
| 01 Jul 2024 - 31 Dec 2024 | 29 Jan 2025 | 27 | 79% | 9% | 12% | 56% |
| 01 Jan 2024 - 30 Jun 2024 | 17 Jul 2024 | 28 | 69% | 15% | 16% | 77% |
| 01 Jul 2023 - 31 Dec 2023 | 01 Feb 2024 | 29 | 72% | 11% | 17% | 61% |
| 01 Jan 2023 - 30 Jun 2023 | 31 Jul 2023 | 33 | 66% | 12% | 20% | 73% |
| 01 Jul 2022 - 31 Dec 2022 | 27 Jan 2023 | 18 | 80% | 15% | 5% | 68% |
| 01 Jan 2022 - 30 Jun 2022 | 01 Aug 2022 | 21 | 74% | 13% | 13% | 70% |
| 01 Jul 2021 - 31 Dec 2021 | 12 Jul 2022 | 23 | 76% | 18% | 6% | 58% |
| 01 Jan 2020 - 30 Jun 2020 | 30 Jul 2020 | 18 | 86% | 13% | 1% | 49% |
| 01 Jul 2019 - 31 Dec 2019 | 15 Jan 2020 | 17 | 95% | 5% | 0% | 62% |
| 01 Jan 2019 - 30 Jun 2019 | 16 Jul 2019 | 16 | 92% | 8% | 0% | 61% |
| 01 Jul 2018 - 31 Dec 2018 | 21 Jan 2019 | 17 | 90% | 10% | 0% | 57% |
| 01 Jan 2018 - 30 Jun 2018 | 23 Jul 2018 | 16 | 96% | 4% | 0% | 52% |
| 01 Jul 2017 - 31 Dec 2017 | 17 Jan 2018 | 19 | 83% | 16% | 1% | 52% |
This information is as reported by the business, and responses are in their own words.
Standard payment terms
Where the supplier does not explicitly state their payment terms the Company uses its own standard payment terms, which are 60 days from the date of the invoice. For intercompany invoices the standard terms are either 60 days or 30 days. For all other suppliers the terms are taken from those stipulated on the invoice and range from 0 (immediate payment) to 30 days. Around 40% of all invoices paid in the reporting period required immediate payment. Payment runs are performed each week and all those invoices which are identified by the system (terms are maintained in the master data) as due and those which will become due in the following week are flagged for payment. A BACS run is performed on the same day with payment reaching the supplier within the next few days. Priority/same day payments are also performed as and when required.
Were there any changes to the standard payment terms in the reporting period?
No information available
Any other information about payment terms
No additional information
Maximum contractual payment period agreed
60
Disputes are rare and resolution is handled on a case-by-case basis. The company seeks to resolve disputes as quickly as possible.
Has this business signed up to a code of conduct or standards on payment practices?
For example, signatories to The Prompt Payment Code must commit to paying 95% of their invoices within 60 days.
❌
Does this business offer e-invoicing in relation to qualifying contracts?
This is where suppliers can electronically submit and track invoices. It's not just allowing suppliers to email them an invoice.
❌
Does this business offer supply chain finance?
This is where a supplier who has submitted an invoice can be paid by a third-party finance provider earlier than the agreed payment date. The business would then pay the finance provider the invoiced sum.
❌
Under its payment practices and policies, can this business deduct sums from payments under qualifying contracts as a charge for remaining on a supplier list?
❌
During the reporting period, did the business deduct sums from payments as a charge for remaining on a supplier list?
No information available
CSL Behring UK Limited is a leading global biotechnology company that specializes in the development and manufacture of innovative biotherapies for the treatment of rare and serious diseases. The company is committed to sustainability and has implemented various initiatives to reduce its environmental impact.
The company's sustainability program includes reducing energy consumption, implementing recycling and waste reduction measures, and promoting sustainable sourcing and production practices. CSL Behring UK Limited also supports community and charitable initiatives through its corporate social responsibility programs.
The company's product portfolio includes a range of life-saving and life-enhancing therapies for conditions such as haemophilia, primary immunodeficiency, and respiratory diseases. These products are manufactured using advanced technologies and processes to ensure safety and quality.
Key people at CSL Behring UK Limited include the managing director, Mark Kilkenny, and the head of operations, Rachel Ingham. The company's registered office address is Marlow International, The Parkway, Marlow, Buckinghamshire SL7 1YL.
CSL Behring UK Limited's website (www.cslbehring.co.uk) provides detailed information about the company's products, sustainability efforts, and corporate social responsibility initiatives. Customers and stakeholders can also find contact information and access resources such as patient support programs and educational materials on the website.
Proud of your payment record? Show your live score on your own site:
<iframe src="https://paymentcheck.co.uk/badge/01622483" width="240" height="72" style="border:0" title="PaymentCheck Score" loading="lazy"></iframe>